Exelixis’ Cabometyx R&D On Track Despite Pivotal Kidney Cancer Setback
The US firm’s Cabometyx has missed the mark in combination with Roche’s Tecentriq in a challenging kidney cancer setting, but analysts argue the setback is minimal as they highlight two major readouts coming this year.
You may also be interested in...
The French drugmaker’s tyrosine kinase inhibitor has met the progression-free survival primary endpoint in combination with Roche’s Tecentriq in a metastatic prostate cancer trial, edging closer to a large market opportunity after a trio of recent failures in other indications.
The mid-sized company is under siege from hedge fund Farallon and faces a fight over its R&D strategy to follow aging blockbuster Cabometyx.